Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium 62.5 mcg once daily vs placebo in COPD (China, 24 weeks)
CTR20160534Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of umeclidinium in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Sep 2016; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20160534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160534.